Bioprospect signs deal with US company Diversa
20 December, 2002 by Pete YoungListed company BioProspect has signed a pact with a second major drug developer interested in testing its library of compounds extracted from Australian plants.
Taxing moves in bioindustry
19 December, 2002 by Pete YoungAustralian bioindustry has a sweeping wish list of tax reform measures it desperately wants to see implemented. The trouble is, forcing through significant changes to the national tax structure has the same torturously long gestation period as developing a major new drug.
Bioscientists appointed to innovation board
12 December, 2002 by Melissa TrudingerSeveral prominent bioscientists, including Prof Adrienne Clarke, Prof Peter Doherty, Cerylid's Jackie Fairley and Prof Alan Trounson, have been appointed to the Victorian government's new Innovation Economy Advisory Board, set up to drive innovation across the state's economy.
Commercialisation: Doing the hard-sell on research
10 December, 2002 by David BinningMuch to the chagrin of those actually at the coalface, the technical achievements of our leading scientific institutions and successful partnering with industry to bring them to market have long been tainted by the myth that not enough is being done and other countries are doing it better.
NSW govt launches BioLink business alliance
10 December, 2002 by Iain ScottThe NSW government has pledged $2.6 million over the next four years towards the establishment of a new business alliance created by the Garvan Institute of Medical Research, the Westmead research hub and the Hunter Medical Research Institute.
National priorities allow room for biotech
09 December, 2002 by Graeme O'NeillBetween the broad brushstrokes of the Federal government's four National Research Priorities, announced last Friday by Prime Minister John Howard, there is room for a major contribution from Australia's biotechnology and biomedical researchers.
European research program thrown open to Aussies
04 December, 2002 by Melissa TrudingerAustralian researchers have the opportunity to participate in the Sixth Framework Program for European Research and Technological Development (FP6), but they should think hard about the value they can bring to collaborative projects and be prepared to come with their own funding, according to presenters at a special symposium held by the Australasian Research Management Society at the Australian Health and Medical Research Congress (AHMRC) last week.
PanVax collaborates with the Institute Pasteur
02 December, 2002 by Melissa TrudingerPrima BioMed subsidiary PanVax has entered into a research collaboration with the Institute Pasteur in France.
Khan resumes Biota board campaign
02 December, 2002 by Pete YoungThe majority shareholder in Biota Holdings, Perth lawyer Farooq Khan, has resumed his campaign to force his way onto the listed biotech's board.
Rebirth for R&D Start
29 November, 2002 by Pete YoungThe controversial seven-month freeze on Federal government R&D Start grants has thawed and AusIndustry is bracing itself for a pent-up flood of fresh applications.
Nextec sets up incubator for early-stage biotechs
27 November, 2002 by Melissa TrudingerMelbourne-based Nextec BioSciences has established an incubator facility for aspiring and early-stage biotech companies.
Ring the Bells
25 November, 2002 by Iain ScottIn its first year of publishing, Australian Biotechnology News has won four awards at the prestigious Australian Business Publishers Bell awards, held in Sydney last week.
QBF chief named
25 November, 2002 by Pete YoungThe Queensland government has chosen a bioscientist with extensive overseas big pharma and commercial experience to head its $100 million life science venture capital fund.
Retiring BresaGen CEO reflects on 15 years at the cutting edge
25 November, 2002 by Graeme O'NeillAs CEO of Adelaide's BresaGen, Dr John Smeaton is no doubt familiar with the ancient Chinese curse: "May you live in interesting times".
Kolling director wins Ramaciotti medal
22 November, 2002 by Susan WilliamsonProf Rob Baxter, Director of the Kolling Institute of Medical Research at the Royal North Shore Hospital and head of the Department of Molecular Medicine at the University of Sydney, has been awarded the 2002 Ramaciotti medal and $20,000 for his research on insulin-like growth factors and their binding proteins.
